TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has announced the application for quotation of 212,170 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code DXB. This move is part of an employee incentive scheme, indicating the company’s efforts to motivate and retain talent, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative pharmaceutical products. The company is involved in creating therapies for unmet medical needs, particularly in the area of kidney disease.
Average Trading Volume: 1,497,148
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$309.1M
For an in-depth examination of DXB stock, go to TipRanks’ Overview page.